GlassScriptPhysician profile
Ruth L Goldman
NPI 1003093188
$3,616.50
in general payments reported to CMS, 2019-2025
15 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $383 · 2021: $845 · 2022: $687 · 2023: $372 · 2024: $458 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $626.00 | 2019-2024 | Myday Contact Lens |
| Sight Sciences, INC. | $531.69 | 2020-2024 | Tearcare System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $482.15 | 2019-2021 | |
| Glaukos Corporation | $414.32 | 2021-2025 | Idosetr, Photrexa |
| Alcon Vision LLC | $395.65 | 2020-2024 | Dailies Total1, Precision 1, Total30 |
| Abbvie INC. | $273.15 | 2022-2024 | |
| Allergan, INC. | $145.13 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $143.16 | 2021 | |
| Bausch & Lomb Americas INC. | $128.50 | 2023 | Infuse |
| Ocular Therapeutix, INC. | $125.00 | 2023 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $119.76 | 2025 | Xdemvy |
| Dompe US, INC. | $117.86 | 2021 | |
| Visioneering Technologies, INC. | $52.95 | 2025 | |
| Optovue, INC. | $39.49 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $21.69 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.